1. Home
  2. BTG vs RYTM Comparison

BTG vs RYTM Comparison

Compare BTG & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo B2Gold Corp

BTG

B2Gold Corp

HOLD

Current Price

$4.58

Market Cap

5.4B

ML Signal

HOLD

Logo Rhythm Pharmaceuticals Inc.

RYTM

Rhythm Pharmaceuticals Inc.

HOLD

Current Price

$94.98

Market Cap

5.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BTG
RYTM
Founded
2006
2008
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.4B
5.8B
IPO Year
2007
2017

Fundamental Metrics

Financial Performance
Metric
BTG
RYTM
Price
$4.58
$94.98
Analyst Decision
Buy
Strong Buy
Analyst Count
2
14
Target Price
$6.00
$131.14
AVG Volume (30 Days)
20.0M
555.5K
Earning Date
05-06-2026
05-05-2026
Dividend Yield
1.86%
N/A
EPS Growth
N/A
28.34
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$38.08
$55.34
Revenue Next Year
$28.46
$86.06
P/E Ratio
$34.75
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.31
$60.99
52 Week High
$6.29
$122.20

Technical Indicators

Market Signals
Indicator
BTG
RYTM
Relative Strength Index (RSI) 52.79 63.09
Support Level $4.32 $82.43
Resistance Level $4.89 $100.69
Average True Range (ATR) 0.19 4.46
MACD 0.03 0.65
Stochastic Oscillator 78.43 82.82

Price Performance

Historical Comparison
BTG
RYTM

About BTG B2Gold Corp

B2Gold Corp is an international, low-cost, senior gold mining company. It has three operating open-pit gold mines in Mali, Namibia, and the Philippines and numerous exploration projects across four continents. Other assets include the Gramalote gold projects. The company focuses on acquiring and developing interests in mineral properties with a primary focus on gold deposits as gold production forms all its revenue. The company's reportable operating segments include its mining operations and development projects, namely Fekola; Masbate; Otjikoto; the Goose Project, and other mineral properties; and corporate and other.

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.

Share on Social Networks: